{'fraction_non_alphanumeric': 0.027184466019417475, 'fraction_numerical': 0.005825242718446602, 'mean_word_length': 5.972972972972973, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Activation of tumor‐specific T cells by dendritic cells expressing the NY‐ESO‐1 antigen after transfection with the cationic lipophosphoramide KLN5

Genetic modification of human monocyte‐derived dendritic cells (DC) with cDNA sequences encoding tumor‐associated antigens (TAA) is a promising strategy for cancer immunotherapy. The present study aimed to develop a nonviral gene transfer method based on the use of the cationic lipophosphoramide reagent, KLN‐5, as an alternative to the commonly used viral vectors.